1. A5.10 Increases in serum cholesterol with baricitinib treatment are associated with favourable changes in apolipoprotein content and with improvement in DAS28-CRP in patients with rheumatoid arthritis. (13th February 2015) Authors: Kremer, J; Genovese, MC; Keystone, E; Taylor, P; Zuckerman, SH; Schlichting, DE; Nantz, E; Beattie, SD; Macias, WL Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 1 Page Start: A51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A7.16 Characterisation of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis in two phase 3 studies. (24th February 2016) Authors: Emery, P; McInnes, I; Genovese, MC; Smolen, JS; Kremer, J; Dougados, M; Schlichting, DE; Rooney, T; Issa, M; de Bono, S; Macias, WL; Rogai, V; Zuckerman, SH; Taylor, PC Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 1 Page Start: A62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A7.17 Effects of baricitinib on multibiomarker disease activity scores and their components in a phase 2b study in moderate-to-severe rheumatoid arthritis patients. (24th February 2016) Authors: Taylor, PC; Genovese, MC; Keystone, E; Weinblatt, M; Rancourt, J; Nantz, E; Schlichting, DE; Zuckerman, SH; Macias, WL Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 1 Page Start: A62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A8.5 Baricitinib effects on serum cholesterol and circulating lipid particles in a phase 2B study in patients with rheumatoid arthritis. (13th February 2015) Authors: Kremer, J; Genovese, MC; Keystone, E; Taylor, P; Zuckerman, SH; Schlichting, DE; Beattie, SD; Macias, WL Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 1 Page Start: A83 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FRI0242 Association between clinical and radiographic responses, and physical function in a phase 3 study of sarilumab plus methotrexate in patients with active, moderate-to-severe rheumatoid arthritis. (15th June 2017) Authors: Genovese, MC; Hoogstraten, H van; Kampman, W; Jayawardena, S; Huizinga, TW Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 576 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OP0201 A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s). (15th June 2017) Authors: Nash, P; Kirkham, B; Okada, M; Rahman, P; Combe, B; Adams, DH; Kerr, LN; Lee, CH; Shuler, CL; Genovese, MC Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. OP0248 Serious infection and associated risk factors in patients with moderate to severe rheumatoid arthritis treated with baricitinib. (15th June 2017) Authors: Winthrop, KL; Genovese, MC; Harigai, M; Chen, L; Dickson, CL; Hyslop, DL; Nishikawa, A; Bradley, JD; Dougados, M Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. SAT0180 Efficacy and safety of sarilumab 200 MG Q2W administered as combination therapy or monotherapy in different patient populations with active RA. (15th June 2017) Authors: Genovese, MC; Fleischmann, R; Hoogstraten, H van; Mangan, EK; Jayawardena, S; Burmester, GR Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 838 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THU0205 Effects of the jak1-selective inhibitor filgotinib on multibiomarker disease activity scores in patients with active rheumatoid arthritis and an inadequate response to methotrexate. (15th June 2017) Authors: Genovese, MC; Li, W; Goyal, L; Pan, Y; Aa, A Van der; Jamoul, C; Harrison, P; Tasset, C; Galien, R; Tarrant, J Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 281 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗